<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=13_Chaetocin_Conversation_Tips</id>
		<title>13 Chaetocin Conversation Tips - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=13_Chaetocin_Conversation_Tips"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=13_Chaetocin_Conversation_Tips&amp;action=history"/>
		<updated>2026-04-26T08:17:53Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=13_Chaetocin_Conversation_Tips&amp;diff=129006&amp;oldid=prev</id>
		<title>Shirt65link: Створена сторінка: Consistent with the findings in the other groups, patients with partially inactive p53 pathways had a longer BCSS and DFS than cases with completely inactive p5...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=13_Chaetocin_Conversation_Tips&amp;diff=129006&amp;oldid=prev"/>
				<updated>2017-01-09T11:42:00Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: Consistent with the findings in the other groups, patients with partially inactive p53 pathways had a longer BCSS and DFS than cases with completely inactive p5...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Consistent with the findings in the other groups, patients with partially inactive p53 pathways had a longer BCSS and DFS than cases with completely inactive p53 pathways [(HR 3.97; 95% CI 2.2�C7.2; p  MDM2, Bcl2, p21 and low Bax, indicating partially inactive p53 transcription pathways. BCSS, DSF and MFS of cases with concomitant expression of p53 and [http://www.selleckchem.com/products/chaetocin.html Chaetocin nmr] MDM4 (p53+/MDM4+/MDM2��/Bcl2��/p21��) were similar to those with a p53?/MDM4+ phenotype, despite the fact that the latter group included a higher percentage of ER+ (p  cancers (p [http://www.selleckchem.com/products/daprodustat.html Daprodustat mw] and [https://en.wikipedia.org/wiki/Tuclazepam tuclazepam] favourable clinicopathological characteristics indistinguishable from those with exclusive MDM4 over-expression (p53��/MDM4+/MDM2?/Bcl2��/p21��). When Nottingham/Tenovus cases with concomitant negative expression of MDM4 and MDM2 were stratified according to p53, Bcl2 and p21 co-expressions, six phenotypes with four clinical outcomes ranging from moderate to extremely poor prognosis were identified: (a) Patients with p53?/MDM4?/MDM2?/Bcl2+/p21�� tumours were characterized by moderate prognosis and favourable clinicopathological features. Compared to patients with tumours displaying a p53?/MDM4?/MDM2?/Bcl2?/p21? phenotype, they were associated with slightly better prognosis (HR 1.47; p = 0.035), lower histological grade (p&lt;/div&gt;</summary>
		<author><name>Shirt65link</name></author>	</entry>

	</feed>